Point72 Hong Kong LTD Arvinas, Inc. Transaction History

Point72 Hong Kong LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$36.38 - $52.31 $30,595 - $43,992	841 New	841 $34,000
Q3 2022 Nov 14, 2022	BUY	$41.87 - $57.99 $317,835 - $440,202	7,591 New	7,591 $338,000
Q4 2021 Feb 14, 2022	SELL	$65.85 - $96.21 $188,528 - $275,449	-2,863 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$73.2 - $107.87 $112,801 - $166,227	-1,541 Reduced 34.99%	2,863 $235,000
Q2 2021 Aug 16, 2021	BUY	$60.45 - $84.26 $266,221 - $371,081	4,404 New	4,404 $339,000
Q4 2020 Feb 16, 2021	SELL	$20.19 - $84.93 $15,929 - $67,009	-789 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$22.99 - $36.34 $18,139 - $28,672	789 New	789 $19,000
Q1 2020 May 15, 2020	SELL	$33.0 - $54.5 $14,487 - $23,925	-439 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$15.39 - $44.38 $16,929 - $48,818	-1,100 Reduced 71.47%	439 $18,000
Q3 2019 Nov 14, 2019	BUY	$21.55 - $27.61 $28,769 - $36,859	1,335 Added 654.41%	1,539 $33,000
Q2 2019 Aug 14, 2019	BUY	$15.96 - $23.8 $3,255 - $4,855	204 New	204 $4,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $997M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.